Breast cancer predorminantly affects women. But men can also develop the disease. There are over 2,400 new cases of breast cancer in men in the USA. Now a new study, led by researchers from the University of Leeds, University of Leicester, and Semmelweis University, reveals that two proteins, eIF4E and eIF5, are linked with male breast cancer. The finding may improve the treatment of men with breast cancer. The paper, titled "A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer", is published in the journal Clinical Cancer Research. The incidence of male breast cancer is increasing. Clinical trials of treatments for breast cancer are all conducted in women. It is unclear whether the mechanism underlying female and male breast cancer is similar. The researchers analyzed tumor samples from 697 men with breast cancer and discovered that men whose tumors expressed two proteins,eIF4E and eIF5, were less likely to survive breast cancer compared to men whose tumors did not express the proteins. Matthew P. Humphries, study first author, noted that breast cancer men which high levels of the two proteins were much more likely to die of their disease. eIF4E and eIF5 may be therapeutic target for male breast cancer. Further independent validation is required to validate the findings. These studies may help ensure all patients receive the most appropriate treatment and are given the best chance of survival. Cusabio provides eIF4E and eIF5 and Recombinant PTPRA.